ArticleBritish journal of cancer2013
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Neutrophil to Lymphocyte Ratio and Spontaneous Bacterial Peritonitis among Cirrhotic Patients: A Systematic Review and Meta-analysis.Canadian journal of gastroenterology & hepatology · 2022Pooled it
- The Prognostic Significance of Combined Pretreatment Fibrinogen and Neutrophil-Lymphocyte Ratio in Various Cancers: A Systematic Review and Meta-Analysis.Disease markers · 2020Pooled it
- The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Prognostic significance of bone marrow and spleenScientific reports · 2021Trial
- MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.International journal of clinical oncology · 2018Trial
- The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Trial
- The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients.Medical oncology (Northwood, London, England) · 2014Trial
- Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.International journal of clinical oncology · 2026Article
- Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer.Future science OA · 2025Article
- Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC.Clinical and translational science · 2025Article
- Prognostic value of systemic inflammation markers in early stage non-small cell lung cancer.Scientific reports · 2025Article
- Predictive strength of inflammatory scores for in-hospital mortality in infective endocarditis.Herz · 2025Article
- Role of Blood Cell Indexes in Progresses to ESRD.Indian journal of clinical biochemistry : IJCB · 2025Article
- Article
- Predictive value of neutrophil-to-lymphocyte ratio for long-term adverse outcomes in cirrhosis patients post-transjugular intrahepatic portosystemic shunt.Scientific reports · 2025Article
- A multi-algorithm prognostic model combining inflammatory indices and surgical features in distal cholangiocarcinoma.Frontiers in oncology · 2025Article
- Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.Cancer medicine · 2025Article
- Association of the derived neutrophil-to-lymphocyte ratio with cardiovascular and all-cause mortality.PloS one · 2025Article
- Clinical diagnostic value of methylated SEPT9 combined with NLR, PLR and LMR in colorectal cancer.BMC gastroenterology · 2024Article
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation has a critical role in the pathogenesis and progression of cancer. Recently, the derived neutrophil to lymphocyte ratio (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been shown to influence clinical outcome in various cancer entities. In this study, we analysed the dNLR with clinical outcome in stage II and III colon cancer patients.
methodsThree-hundred and seventy-two patients with stage II and III colon cancer were included in this retrospective study. Kaplan-Meier curves and multivariate Cox proportion analyses were calculated for time to recurrence (TTR) and overall survival (OS).
resultsIn univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (hazard ratio (HR) 2.38, 95% confidence interval (CI) 1.57-3.6, P<0.001) and remained significant in multivariate analysis. Patients with dNLR >3 had a median TTR of 83 months, and patients with dNLR ≤ 3 showed a median TTR of 132 months. In OS analysis, a dNLR >2.2 was significantly associated with decreased OS in univariate (HR 1.85, 95% CI 1.11-3.08, P=0.018) and multivariate analysis. Patients with dNLR >2.2 showed a median OS of 121 months, and patients with dNLR ≤ 2.2 had a median OS of 147 months.
conclusionThe dNLR may be an independent prognostic marker for TTR and OS in patients with stage II and III colon cancer. Independent validation of our findings is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.